Showing results (231-240 of 280) with videos related to
Sort By:
Pageof 28
Molecular Cancer Research : MCR|March 9, 2016
Development of a Novel c-MET-Based CTC Detection PlatformTian Zhang, Rengasamy Boominathan, Brad Foulk, et al.Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.Cancer Medicine|March 2, 2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancerAndrew J Armstrong, George J Netto, Michelle A Rudek, et al.Cancer|November 16, 2021
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920Hamid Emamekhoo, Mark R Olsen, Bradley C Carthon, et al.NEJM Evidence|May 30, 2024
Prostate Cancer Foundation Screening Guidelines for Black Men in the United StatesIsla P Garraway, Sigrid V Carlsson, Yaw A Nyame, et al.The New England Journal of Medicine|October 11, 2016
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyAlain Ravaud, Robert J Motzer, Hardev S Pandha, et al.Cancers|August 12, 2022
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell CarcinomaYu-Wei Chen, Matthew D Tucker, Landon C Brown, et al.JCO Precision Oncology|November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate CancerAndrew J Armstrong, Jun Luo, David M Nanus, et al.The Lancet. Oncology|January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialAndrew J Armstrong, Susan Halabi, Tim Eisen, et al.Pageof 28